WallStreetZenWallStreetZen

NASDAQ: BCRX
Biocryst Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

BCRX past revenue growth

How has BCRX's revenue growth performed historically?
Company
22.37%
Industry
144.63%
Market
17.55%
BCRX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
BCRX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
BCRX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

BCRX earnings and revenue history

Current Revenue
$331.4M
Current Earnings
-$226.5M
Current Profit Margin
-68.4%

BCRX Return on Equity

Current Company
N/A
Current Industry
-63.5%
Current Market
188%

Be the first to know when BCRX announces earnings.

BCRX Return on Assets

Current Company
-43.6%
Current Industry
2.9%
BCRX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

BCRX Return on Capital Employed

Current Company
-32.15%
Current Industry
19.5%
BCRX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BCRX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
BCRX$331.41M-$116.34M-$226.54M+74.21%N/A
SLN$32.12M-$60.37M-$54.77M+216.26%N/A
IMTX$58.69M-$97.57M-$105.43M+69.15%N/A
ALXO$0.00-$158.40M-$160.81M-100.00%N/A
RLAY$25.55M-$336.70M-$341.97M-88.41%N/A
View Top Biotech Stocks

BCRX earnings dates

Next earnings date
Jun 12, 2024

Biocryst Pharmaceuticals Earnings & Revenue FAQ

What were BCRX's earnings last quarter?

On Invalid Date, Biocryst Pharmaceuticals (NASDAQ: BCRX) reported Q4 2023 earnings per share (EPS) of -$0.31, up 18.42% year over year. Total Biocryst Pharmaceuticals earnings for the quarter were -$61.73 million. In the same quarter last year, Biocryst Pharmaceuticals's earnings per share (EPS) was -$0.38.

If you're new to stock investing, here's how to buy Biocryst Pharmaceuticals stock.

What was BCRX's earnings growth in the past year?

As of Q2 2024, Biocryst Pharmaceuticals's earnings has grown year over year. Biocryst Pharmaceuticals's earnings in the past year totalled -$226.54 million.

What is BCRX's earnings date?

Biocryst Pharmaceuticals's earnings date is Invalid Date. Add BCRX to your watchlist to be reminded of BCRX's next earnings announcement.

What was BCRX's revenue last quarter?

On Invalid Date, Biocryst Pharmaceuticals (NASDAQ: BCRX) reported Q4 2023 revenue of $93.40 million up 17.42% year over year. In the same quarter last year, Biocryst Pharmaceuticals's revenue was $79.55 million.

What was BCRX's revenue growth in the past year?

As of Q2 2024, Biocryst Pharmaceuticals's revenue has grown 22.37% year over year. This is 122.26 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Biocryst Pharmaceuticals's revenue in the past year totalled $331.41 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.